Immunic (IMUX)

• Market cap: $187M
• 1 day: -2.14%
• 5 days: 13.97%
• 1 month: 17.58%
• 3 months: 18.19%
• 6 months: 128.5%
• Year to date: 135.16%
• 1 year: 66.99%
• 5 years: -89.74%
• 10 years: -99.58%
• Sector: Healthcare
• Industry: Biotechnology

About: Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Employees: 95